Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Follow the links below to read about each product:
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
about 2 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)about 2 years ago
A New Era of Ethical Leadershipabout 2 years ago
Survival Story: Enhertuabout 2 years ago
Gut Instinct: Rebyotaabout 2 years ago
Delaying Disease Onset: Tzieldabout 2 years ago
New Beginnings: Sunlencaabout 2 years ago
A Heartfelt Solution: Camzyosabout 2 years ago
Fortifying Defenses Pre-Patent Cliffabout 2 years ago
New Product Planning: The Function's Evolution in Pharmaabout 2 years ago
No Rate Relief in Sight for BiotechNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bob Mauch: Strengthening the Chain
2
Novo Nordisk Stock Reacts to Recent Board Changes
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
